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1. Introduction 
1.1 Carotid stenosis and atheromatous process 
Carotid artery stenosis due to atherosclerosis is a major complication of hyperlipidemia, 
diabetes mellitus and hypertension. Moreover, the extent of carotid intima media thickness 
is a measure of atheromatosis and therefore of cardiovascular disease (CVD).  
The effect of cholesterol in the process of atheromatosis is now well established. High levels 
of total cholesterol (TC), as well as of low-density lipoprotein (LDL), very low-density 
lipoprotein (VLDL), intermediate-density lipoprotein (IDL), lipoprotein a (Lp-α), and 
triglycerides (TG), coupled with decreased levels of high-density lipoprotein (HDL) are 
responsible for the creation of atheromatous plaques (Assmann & Schulte, 1992; Hokanson 
& Autsin, 1996; Katsouras et al., 2001). Of the above factors, LDL cholesterol, and especially 
the oxidized LDL (oxLDL) is considered as the most important contributor of atheromatosis 
(Anderson et al., 1996).  
The atheromatous process is completed in the following three stages: 
1. In the first stage, LDL cholesterol enters the vessel wall, binds to glucosaminoglucanes, 
which are part of the extracellular matrix of the intima. This binding is facilitated by 
apolipoprotein B-100 (ApoΒ–100). The accumulation of LDL in the vessel wall 
contributes to the formation of fatty strikes. Following adhesion to the vessel wall, LDL 
undergoes oxidation by free radicals produced locally, the molecule is altered and 
chemokines are produced by adjacent vessel wall cells, such as monocyte 
chemoattractant protein-1 (MCP–1), together with growth factors, which are 
responsible for the accumulation of monocytes and macrophages. The latter cause 
further oxidation of LDL, resulting in negative charge, recognition by scavenger 
receptors located on macrophage membrane and increased uptake of LDL inside the 
macrophages, as these receptors are not inhibited by increased intracellular 
concentration of cholesterol. The final result is an enormous accumulation of LDL in the 
macrophages, which are transformed to foam cells. These cells represent the first step in 
the atheromatous process (Durrington & Sinderman, 2002) (figure 1). 
2. During the second stage, the atheromatous plaque is formed. Foam cells produce 
growth factors and together with oxLDL result to the attraction of smooth muscle cells. 
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The latter are then differentiated to fibroblasts and start producing collagen. This 
collagen covers foam cells, which either are destroyed or are forced to apoptosis. The 
final result is the formation of a pool of extracellular cholesterol trapped under a fibrous 
capsid (figure 2). The part which is close to the yet intact vessel wall is the active site of 
the plaque, where the foam cells are produced. As the plaque extents to the inner layers 
of the vessel wall, the point of foam cell formation becomes instable and may cause 
rapture of the plaque (Durrington & Sinderman, 2002) (figure 3).  
3. In the third stage, that of the complicated lesion, the rapture of the fibrous capsid of the 
atheromatous plaque leads to massive evacuation of the cholesterol reservoir. The 
artery may occult due to the accumulation of platelets and subsequent clotting, leading 
to acute ischemia or infarction (figure 4). If not so, then the plaque will be further 
enlarged (Durrington & Sinderman, 2002). 
 
Fig. 1. Atherogenesis. Fatty strikes are characterized by macrophages containing an excess of 
lipids (foam cells). Foam cells are derived by blood monocytes which are attracted to vessel 
intima and start phagocytosing lipoproteins, such as oxLDL. The conversion of fatty strike 
to atheroma depends on proliferation and differentiation of smooth muscle cells to 
fibroblasts. The latter produce collagen resulting in intima thickening. As the lesion extents 
further, foam cells are destroyed releasing large amounts of cholesterol trapped in a fibrous 
capsid. The active site of atheroma is the point which is adjacent to normal endothelium, 
where foam cells are formed (adopted with persmission from Durrington & Sinderman, 
2002). 
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Avoiding the formation and the instability of the atheromatous plaque is top priority for 
patients at risk for cardiovascular events. Statins may contribute towards this direction 
(Corti et al., 2002; Nissen et al., 2004) 
 
Fig. 2. Advanced atheromatous plaque causing arterial lumen occlusion of 70% (adopted 
from Durrington & Sinderman, 2002). 
 
Fig. 3. The point of the atheromatous plaque, on which active enlargement occurs: formation 
of new foam cells and increased cholesterol uptake contribute to increased plaque instability 
(adopted from Durrington & Sinderman, 2002). 
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Fig. 4. A raptured ahteromatous plaque, in which the cholesterol reservoir has evacuated 
itself under the fibrous capsid. A clot in the endothelial surface at the site of rapture occults 
the lumen completely (adopted from Durrington & Sinderman, 2002).  
1.2 Oxidized LDL 
Oxidized LDL cholesterol in humans is found mainly in two types:  
a. conjugated form, attached to the atheromatous plaque and  
b. circulating form found in serum.  
Oxidized LDL is produced following oxidation of LDL by free radicals and other oxidadive 
factors, a procedure called oxidative stress. The circulating oxLDL is the measurable fraction 
of oxLDL in plasma. Oxidized LDL is a key element of the pathway leading to the formation 
of the atheromatous plaque and has been extensively studied both as a marker of 
atheromatosis and as a possible target of therapeutic intervention. Circulating oxLDL is 
considered a risk marker for atherosclerosis (Toshima, 2000) and coronary heart disease 
(CHD) ( Ehara et al., 2001; Holvoet et al., 2003; Toshima et al., 2000). Increased oxLDL levels 
in circulation and the vessel wall are associated with endothelial dysfunction (Penny et al., 
2001) in such patients (Ehara et al., 2001; Holvoet et al., 1999; Nishi et al., 2002), contributing 
to atheromatous plaque instability (Ehara et al., 2001).  
Oxidative modification of LDL leads to rapid focal accumulation in macrophages (Witztum 
& Steinberg, 1991), which is the first step of the atheromatous process. The increased 
retention time of LDL in the intima offers enhanced probability to be oxidized by free 
radicals produced by endothelium, smooth muscle cells or macrophages (Steinbrecher et al., 
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1984). Oxidized LDL then acts chemotactic for monocytes and smooth muscle cells through 
binding to scavenger receptors (D. Li et al., 2002), leading to the formation of foamy cells. 
Oxidized LDL is also capable to elicit endothelial dysfunction by altering the secretory 
activity of endothelial cells (D. Li et al., 2002), inhibiting the nitric oxide-mediated 
vasodilatation through reduction of the expression of endothelial nitric-oxide synthase 
(eNOS), inducing the expression of adhesion molecules on the endothelium thus mediating 
the adhesion of monocytes to intima (D. Li et al., 2002), and inducing the expression of 
inflammatory cytokines (Steinberg, 1997). Indeed, oxLDL is a potent inducer of 
inflammation (Steinberg et al., 1989), contributing to the chronic inflammatory process 
which results to atherosclerosis  (Ross, 1999). 
1.3 Statins 
The 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors, or statins, reduce serum 
TC, LDL cholesterol, apolipoprotein B (apoB), and, to a lesser degree, TG and Lp-a levels. 
Statins also have pleiotropic effects (Bellosta et al., 2000), such as the modulation of 
inflammatory molecules and monocyte maturation and differentiation (Bellosta et al., 2000), 
the suppression of smooth muscle-cells migration and proliferation (Bellosta et al., 2000), the 
reduction of the monocyte adhesion to the endothelium (Weber et al., 1997), the restoration 
of the impaired endothelium-dependent vessel wall relaxation (Jarvisalo et al., 1999), and 
the modification of cell-mediated LDL oxidation (Giroux et al., 1993; Aviram et al., 1998). All 
of the above mechanisms contribute to the reversion of atheromatosis. Undeniably, statins 
reduce the incidence of coronary events and are a cornerstone in the primary and secondary 
prevention of CHD (D.Y. Li et al., 2001). Previous studies have detected some efficacy in 
reducing the circulating oxLDL levels, but whether this effect is due to the reduction of LDL 
or is an independent, pleiotropic phenomenon remains a matter of controversy (Kwak & 
Mach, 2001; Robinson et al., 2005). Furthermore, little is known about the definite clinical 
benefit of such oxidative marker reduction.  
The aim of the present study was to evaluate the efficacy of atorvastatin in reducing 
stenosis, to investigate the effect on oxLDL and to search for possible associations of oxLDL 
modification with changes of stenosis in patients managed conservatively and in pre-treated 
with percutaneous catheter interventional procedures patients with carotid atheromatosis. 
We hypothesise that atorvastatin therapy will confer remission of oxLDL levels in vivo and 
this will be associated with significant reduction of carotid artery stenosis.  
2. Patients and methods 
Between January 2005 and February 2008 a total of 100 patients were randomly selected 
from the lipid clinic and the carotid angioplasty clinic of a large tertiary hospital in Athens 
for inclusion in the study. Informed consent was obtained from each patient at recruitment 
according to our institutional policies. Eligible were patients with carotid artery 
atheromatosis from various causes (not only dyslipidemia) and with a range of predisposing 
factors. Exclusion criteria included: acute cardiovascular disease, severe or unstable angina 
pectoris, clinically evident cardiac failure, severe arrhythmias, recent surgical procedures, 
inflammatory diseases, active liver disease or liver impairment, excessive alcohol 
consumption (>4 drinks /day) or history of alcohol abuse, known allergic reaction to statins, 
poorly controlled diabetes mellitus as defined by a haemoglobin A1c (HbA1c) level of >7 %, 
www.intechopen.com
 Coronary Artery Diseases 
 
130 
uncontrolled hypertension indicated by systolic blood pressure (SBP) >140 mmHg and/or 
diastolic pressure >85 mmHg, history of deep vein thrombosis, bleeding tendency, serum 
triglycerides >350 mg/dl, evidence of thyroid dysfunction, use of systemic steroids or other 
anabolics, pernicious anaemia, impaired vitamin B12 or folate acid levels, abnormal serum 
urate at baseline, serum creatinine phosphokinase elevation of >1.5 fold at baseline, 
pregnancy or lactation, and end-stage renal disease or dialysis.  
Patients were allocated into two groups according to the degree of carotid artery stenosis: 
those with arterial lumen occlusion of ≥70% in at least one common or internal carotid 
vessel consisted group A; those with stenosis <70% comprised group B. Patients in both 
groups were naive to statin therapy or if otherwise, a 6-month washout period was allowed 
before enrolment in the study. Group A underwent percutaneous transluminal carotid 
angioplasty with stenting by the same interventional cardiologist, prior to the initiation of 
statin therapy. Those patients were additionally administered clopidrogrel and salicylate. 
Both groups had to follow an American Heart Association step II diet and were encouraged 
to exercise.  
According to the study protocol, all patients were placed on atorvastatin once daily at 
bedtime in individualised doses, tittered to achieve and maintain serum LDL cholesterol 
levels of <100 mg/dl (and ideally <70 mg/dl, if hypertension, renal impairment, smoking, 
hyperlipidemia, symptomatic peripheral arterial obstructive disease, or diabetes mellitus 
were present). Patients were prescribed statins even in the absence of hyperlipidemia, as the 
aim of the study was to investigate the effect of statin on oxLDL and carotid stenosis in a 
common atherogenic patient population. The most common doses used to achieve the above 
levels of LDL ranged between 10 to 40 mg, while seldom it was required to administer 
higher doses such as 60 mg (median atorvastatin dose for the total population = 20 mg, 
range 10 – 60 mg). The use of other drugs known to act synergistically with statins causing 
rhabdomyolysis was prohibited during the study. Adverse events were assessed in every 
visit in a non-specific manner: every newly reported symptom was documented as possible 
adverse reaction due to statin therapy and subsequently evaluated by an expert in clinical 
biochemistry. Adherence to the medication regimen was assessed indirectly by the low LDL 
levels compared with baseline.  
Medical anamnesis, anthropometrics, smoking habits, blood pressure, and laboratory 
investigations comprising of complete blood count, fasting glucose, HbA1c, liver and kidney 
biochemistry, detailed lipid profile (TC, LDL cholesterol, HDL cholesterol, serum TG, apoB, 
and apolipoprotein A), urate, B12 and folate, thyroid function tests, homocysteine, Lp-a, and 
oxLDL were obtained at baseline and during follow-up visits, which were arranged at 
baseline, one, three, and six months; the final assessment was carried out in 12 months. 
Blood samples were collected after an at least 12-hour fast and a light, low-fat meal the night 
before sample collection was advised. Venous blood samples were collected in standard 
biochemistry vacutainer tubes. For the analysis of homocysteine and whole blood count, 
ethylenediaminetetraacetic acid (EDTA) vacutainer was used. Serum for biochemistry 
analysis was obtained by centrifugation (4000 g) at 4°C for 7 min and was immediately 
tested.  
Lipid profiles (TC, HDL, TG) were determined using commercially available enzymatic 
colourimetric methods (Dade Behring, Newark, USA) with a Dade Behring analyser. LDL 
was calculated with the use of Friedewald's formula as all had TG <350 mg/dl (Puccetti et 
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al., 2002). For the measurement of circulating oxLDL, a commercially available kit 
(Mercodia, Uppsala, Sweden), based on a double antibody (4E6 and mouse monoclonal 
antiapoB) (Holvoet et al., 1996) capture ELISA test, was used. This method primarily detects 
malondialdehyde LDL (MDA-LDL). The normative range (reference range) in our lab was 
31-61 mU/l. Apolipoprotein A, B and Lp-a were measured using immuno-nephelometry 
with rabbit antisera (Dade Behring, Newark, USA) in a Dade Behring analyser.  
The evaluation of stenosis was conducted by Triplex ultrasonography using an Apogee 800 
plus scanner with a 7.5 MHz transducer (ATL Inc., Bothell WA, USA) at baseline and 12 
months. The stenosis was calculated in three sections in each common and internal carotid 
artery, and the final measure was the mean value of the three. The value of stenosis in the 
most occluded vessel was used in the statistical analysis. Specifically, the internal carotid 
artery (ICA) and common carotid artery (CCA) bilaterally were evaluated for each patient 
using coloured and grey Doppler ultrasonography. An effort was made to completely 
visualize the vessels. Additionally, the pulse wave was estimated with Doppler 
phasmatometry as well as the blood flow velocity of the two vessels. Results were recorded 
in a validated form. Stenosis was defined as the presence of visual plaque in coloured or 
grey Doppler. The degree of stenosis was calculated by measuring the decrease of the lumen 
diameter and the maximum systolic blood flow velocity. In difficult cases, other parameters 
were taken into account, such as ICA/CCA max blood flow velocity ratio and the ICA end-
diastolic velocity. A degree of stenosis >70% was considered as sever and angioplasty was 
advised. A degree of stenosis between 60 – 70% was defined as high, between 50 – 60% as 
moderate and <50% as mild. High, moderate and mild stenoses were treated conservatively. 
The intima media thickness (IMT) and plaque morphology were not studied due to specific 
lab requirements, not readily available in our institution.  
2.1 Statistical analysis 
Continuous variables were presented as mean values ± standard deviation, while qualitative 
variables were presented as absolute and relative frequencies. Normality tests were applied 
using the Kolmogorov-Smirnov criterion as well as Shapiro-Wilk test. Univariate analysis 
was initially applied to test the associations of oxLDL with carotid stenosis for each patient 
group as well as to identify first order correlations with various clinical parameters. 
Correlations between skewed continuous or discrete variables were evaluated using 
Spearman's p-coefficient, whereas correlations of normally distributed variables were 
evaluated by calculating the Pearson's r-coefficient. Comparisons between normally 
distributed, continuous variables and categorical variables were made using the Student t-
test. Analysis of categorical data was carried out with the [chi]2 test or Fischer's exact test 
when appropriate. 
The association of oxLDL with carotid stenosis was also tested through multiple Cox 
proportional hazard model. The results obtained were presented as Hazard Ratios (HR) and 
the 95% Confidence Intervals (CI). A backward elimination procedure was applied to all 
multivariate models (using P<5% as the threshold for removing a variable from the models). 
All models were adjusted for age, gender, SBP and TC. Kaplan-Meier curves concerning 
stenosis over the study period were plotted and Log rank test was performed. All reported 
P-values were based on two-sided tests and compared to a significance level of 5%. STATA 
8.0 software (Stata Corporation, 2003, Texas, USA) was used for the analysis.  
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3. Results 
3.1 Patients’ characteristics 
A total of 612 patients were evaluated, of which 123 fulfilled the eligibility criteria; finally, 
100 had complete data to enter the analysis, 76 males and 24 females, median age 68 years 
(range 45-81). Diabetes mellitus was recorded in 26 of the 100 patients and hypertension in 
66. Twenty patients had metabolic syndrome according to the national cholesterol education 
programme-adult treatment panel III (NCEP-ATP III) criteria (National Cholesterol 
Education Program (NCEP), 2001). Active smoking (defined as current of discontinued as 
far back as 5 years) was reported by 58 patients. Mean atorvastatin dose at baseline was 
24.31±11.49 mg for group A and 20.62±10.39 mg for group B (p=0.1). By the end of the study 
period, the respective mean values were significantly increased to 30.45±16.27 mg for group 
A (p=0.044) and 28.75±17.57 mg for group B (p=0.007). 
Each of the study group (A and B) comprised 50 patients. The two groups were comparable 
with regard of their baseline characteristics (table 1).  
3.2 Lipid profile and oxidzed LDL 
Mean serum TC, LDL-cholesterol, TG, Lp-a, homocysteine, and oxLDL were significantly 
reduced at 12 months compared to baseline (table 2). Specifically, mean oxLDL dropped 
from 62.26±22.03 to 44.49±21.75 mU/l (p<0.001). A marked decrease was noticed during the 
first 6 months and a plateau thereafter (figure 5).  
Characteristic Total  Group A Group B P value 
Males / females 72 / 28 36 / 14 36 / 14  
Mean age in years ± SD 67.57±7.15 68.46±5.71 66.68±8.31 0.21 
Number of pts with DM (percentage) 37 (37%) 18 (36%) 19 (38%) 0.83 
Number of pts with HTN (percentage) 67 (67%) 36 (72%) 31 (62%) 0.29 
Number of smokers (percentage) 54 (54%) 29 (54%) 25 (46%) 0.33 
Number of pts with CAD (percentage) 51 (51%) 24 (47%) 27 (53%) 0.55 
Mean ± SD TC (mg/dl)  232.23±47.8 235.24±49.2  229.22±46.7 0.53 
Mean ± SD LDL cholesterol (mg/dl) 151.27±41.7 154.16±42.8 148.84±40.9 0.52 
Mean ± SD HDL cholesterol (mg/dl) 51.97±12.7 52.12±12.1 51.82±13.4 0.9 
Mean ± SD TG (mg/dl) 145.59±73.1 146.04±73.2 145.14±73.7 0.95 
Mean ± SD oxLDL (mU/l) 64.66±24.8 65.8±25.3 63.53±24.5 0.65 
Mean ± SD homocysteine (mU/l) 13.99±4.8 13.5±4.6 14.47±5.1 0.32 
Pts: patients, DM: diabetes mellitus, HTN: arterial hypertension, MS: metabolic syndrome, SD: standard 
deviation, LDL: low density lipoprotein, HDL: high density lipoprotein, CAD: coronary artery disease, 
TC: total cholesterol, TG: triglycerides, oxLDL: oxidized LDL 
Table 1. Study population baseline characteristics. 
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A significant correlation between LDL and oxLDL levels was detected (Pearson's correlation 
coefficient r=0.7, p<0.01) (figure 6). Similar correlation was found between oxLDL and apoB 
levels (r=0.65, p<0.001), while no significant correlation was shown with Lp-a.  
Between smokers mean oxLDL was reduced from 60.68±24.09 at baseline to 45.84±24.89 mU/l 
at the end of study period (difference 14.84 mU/l, p = 0.0036). Similarly, between non-smokers 
it was reduced from 69.33±25.11 to 40.36±5.6 mU/l (difference 28.97 mU/l, p<0.001). Non-
smokers had approximately double decline of oxLDL levels compared to smokers. Carotid 
artery stenosis was reduced between smokers from 29.68±25.59% at baseline to 23.06±21.71% 
at 12 months (p = 0.002). Non-smokers also presented significant reduction of stenosis during 
the study period (24.67 ± 26.22% vs 20 ± 21.45%, p = 0.004). Non-smokers and smokers had 
similar decline of carotid stenosis in 12 months (6.61% vs 4.67%, table 3). 
Investigations  Total  Group A Group B 
TC (mg/dl) baseline 
TC (mg/dl) 12 months 
p value 
232.23 ± 47.8 
153.36±17.2 
<0.0001 
235.24±49.1 
154.24±16.9 
<0.0001 
229.22±46.7 
152.48±17.7 
<0.0001 
LDL cholesterol (mg/dl) baseline 
LDL cholesterol (mg/dl) 12 months 
p value 
151.5±41.7 
79.75±12.7 
<0.0001 
154.16±42.8 
79.54±13.2 
<0.0001 
148.84±40.9 
79.96±12.3 
<0.0001 
TG (mg/dl) baseline 
TG (mg/dl) 12 months 
p value 
145.59 ± 73.1  
111±53.1 
0.0002 
146.04±73.2 
112.1±54.7 
0.01 
145.14±73.7 
109.9±51.96 
0.0069 
OxLDL (mU/l) baseline 
OxLDL (mU/l) 12 months 
p value 
64.67±24.8 
43.38±18.9 
<0.0001 
65.8±25.3 
42.16±17.6 
<0.0001 
63.53±24.6 
44.65±26.1 
0.0007 
HDL cholesterol (mg/dl) baseline 
HDL cholesterol (mg/dl) 12 months 
p value 
51.97±12.7 
51.32±15.5 
0.74 
52.12±12.1 
52.22±16.3 
0.97 
51.82±13.4 
50.42±14.8 
0.62 
Homocysteine (mg/dl) baseline 
Homocysteine (mg/dl) 12 months 
p value 
13.99±4.8 
11.89±3.5 
0.0006 
13.5±4.6 
11.88±3.8 
0.057 
14.48±5.1 
11.9±3.4 
0.0036 
Apolipoprotein A (mg/dl) baseline 
Apolipoprotein A (mg/dl) 12 months 
p value 
156.57±26.7 
160.35±25.3 
0.3 
156.46±27.3 
162.02±23.7 
0.28 
156.68±26.4 
158.68±27.1 
0.7 
Apolipoprotein B (mg/dl) baseline 
Apolipoprotein B (mg/dl) 12 months 
p value 
129.95±31.3 
77.1±11.8 
<0.0001 
131.84±31.4 
77.58±13.1 
<0.0001 
128.05±31.4 
76.62±10.47 
<0.0001 
Lp-a (mg/dl) baseline 
Lp-a (mg/dl) 12 months 
p value 
25.08±23.8 
27.72±29.1 
0.48 
25.67±24.1 
29.42±29.8 
0.49 
24.47±23.8 
26.01±28.7 
0.77 
LDL: low density lipoprotein, HDL: high density lipoprotein, TC: total cholesterol, TG:triglycerides, 
oxLDL: oxidized LDL, Lp-a: lipoprotein a  
Table 2. Comparison of mean ± standard deviation and respective P-values of measured 
laboratory investigations at baseline and 12 months, in the total population, and the two 
groups. 
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TC: total cholesterol, LDL: low density lipoprotein cholesterol, oxLDL: oxidized LDL, TG: triglycerides, 
0=baseline, 1=one month, 2=three months, 3=six months, 4=twelve months. 
Fig. 5. Time curve of change of total cholesterol, LDL cholesterol, triglycerides and oxidized 
LDL levels during the observation period.  
 
LDL: low density lipoprotein cholesterol, oxLDL: oxidized LDL, CI: confidence intervals. 
Fig. 6. Correlation of low density lipoprotein with oxidized LDL levels at baseline (Pearson’s 
correlation coefficient r=0.7, p<0.001). 
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In further analysis, the group of smokers was subdivided to mild (≤5 cigarettes/day), 
moderate (5 – 15 cigarettes/day) and heavy (≥15 cigarettes/day) smokers. The statistical 
significant reduction of oxLDL levels and degree of carotid stenosis was apparent in the 
subgroup of mild smokers (oxLDL at baseline 48.24±8.74 mU/l vs 41.54±9 mU/l at 12 
months, p = 0.027 and stenosis at baseline 27.63±25.68% vs 23.42±21.74% at 12 months, p = 
0.009), while it was not apparent in the subgroups of moderate and heavy smokers (oxLDL 
at baseline 86.82±37.7 mU/l vs 42.92±10.77 mU/l at 12 months, p = 0.077 and stenosis at 
baseline 34±31.9% vs 22±24.9% at 12 months, p = 0.186, for moderate smokers; respective 
values for oxLDL were 66.29±15.88 mU/l vs 34.81±5.48 mU/l, p = 0.06 and for stenosis 
32.14±24.13% vs 22.86±22.8%, p = 0.174, for heavy smokers). The above described effect of 
smoking was taken into consideration during Cox-regression analysis. 
 Smokers P value Non Smokers P value 
OxLDL (mU/l) 
baseline 
12 months 
difference 
 
60.68±24.09 
45.48±24.89 
14.84 
0.0036 
 
69.33±25.11 
40.36±5.6 
28.97 
0.001 
Stenosis (%) 
baseline 
12 months 
difference 
 
29.68±25.59 
23.06±21.71 
6.61 
0.002 
 
24.67±26.22 
20±21.45 
4.67 
0.004 
Correlation of oxLDL 
change with stenosis 
change in 12 months 
 
Pearson’s 
r = 0.412 
0.021 
 
Pearson’s 
r = 0.198 
0.03 
oxLDL: oxidized LDL. 
Table 3. Comparison of mean oxidized LDL values and degree of carotid stenosis change 
during the 1 year follow-up period, between smokers and non-smokers. 
Within group B, the subgroup of patients with high degree of stenosis (>60%) had oxLDL 
63.47±19.18 mU/l at baseline, while those with moderate and mild degree of stenosis (<60%) 
had 40.32±20.72 mU/l (p<0.001). Corresponding values at 12-months were 33.18±17.78 
mU/l and 38.81±29.02 mU/l, representing a marked decline for patients with >60% initial 
stenosis and a far less decline for patients with <60% initial stenosis; yet those differences 
were not statistically significant (table 4). 
 Stenosis >60<70% Stenosis <60% P value 
Baseline 
Mean oxLDL 
 
63.47±19.18 mU/l 
 
40.32±20.72 mU/l 
 
< 0.001 
12 months             
Mean oxLDL 
 
33.18±17.78 mU/l 
 
38.81±29.02 mU/l 
 
NS 
LDL: low density lipoprotein cholesterol, oxLDL: oxidized LDL, NS: non significant. 
Table 4. Comparison of mean oxidized LDL levels at baseline and 12 months within patients 
of group Β (n = 50), according to degree of stenosis at enrollment. 
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3.3 Anthropometrics 
Body mass index (BMI), weight, waist circumference and waist:hip ratio did not change 
significantly during the study period.  
3.4 Carotid stenosis 
Patients in group A had null stenosis at recruitment due to prior angioplasty with stenting. 
At the end of the 12-month statin therapy, no case of clinically important restenosis (>70%) 
was reported in this group (as restenosis was defined any increase of the carotid lumen 
diameter >5%). Patients in group B had mean percentage of stenosis at baseline 47.6±13.2%, 
which was significantly reduced following 12-month statin therapy (37.7±15.7%, p<0.001) 
(table 5).  
 Baseline 12 months P value 
Mean (%) carotid stenosis ± standard 
deviation 
47.6 ± 13.2 37.7 ± 15.7 0.001 
Table 5. Change of the percentage of carotid artery stenosis between baseline and 12months 
for patients in group B. 
3.5 Association of stenosis with oxidized LDL 
Group B patients in the highest quartile of oxLDL values had a 12-month risk ratio for 
restenosis of 1.025, 95%CI=1.006-1.044, p=0.0083 (figure 7). After adjusting for gender, 
age, smoking, SBP, TC, and LDL levels, these patients demonstrated a HR for restenosis of 
4.319 compared with those in the lowest quartile (p<0.001, figure 7). This means that an 
increase of oxLDL by one unit increases the degree of carotid stenosis by 2.5%, for 
patients in group B. A weak but significant correlation was detected between oxLDL 
levels and the degree of carotid artery stenosis (r=0.17, p=0.018). Similar correlation was 
found between LDL cholesterol levels and carotid stenosis (r=0.18, p=0.0085). The 
strength of Pearson’s correlation of mean oxLDL change with degree of carotid stenosis 
change during the 12-month period was greater for smokers compared to non-smokers 
(table 3).  
3.6 The effect of LDL levels 
Patients in group B who achieved LDL levels <70 mg/dl during the observation period had 
a greater (28.08±28% vs 22.31±22.7%, difference 5.77%, p = 0.06) reduction of carotid stenosis 
compared to those with LDL levels between 70 and 100 mg/dl (26.98±25.3% vs 21.35±21.3%, 
difference 5.63%, p < 0.001), but this difference was not statistically significant. Thus, in 
conservatively treated group B, further reduction of LDL than the limit of 100 mg/dl was 
not associated with additional improvement of stenosis.  
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4. Discussion 
This study demonstrates that atorvastatin administered in indivudualised doses, tittered to 
maintain serum LDL cholesterol levels <100 mg/dl, significantly decreased lipid profile and 
oxLDL, reduced carotid artery stenosis in patients managed conservatively and prevented 
restenosis in patients with prior angioplasty. Oxidized LDL in this study correlated 
positively with the degree of carotid artery stenosis; it was also shown by multivariate 
analysis that oxLDL represented an independent risk factor for restenosis. To our 
knowledge this is the first prospective study with a long observation period of 12 months to 
report such a clear, significant reduction of oxLDL levels following atorvastatin therapy for 
carotid atheromatosis of various causes and to report an association of the degree of oxLDL 
reduction with remission of carotid stenosis. It is also of major importance that this robust, 
long-standing decline of oxLDL was achieved with doses of atorvastatin used in everyday 
clinical practice. Interestingly, this beneficial effect was completed in the first six months, 
while practically no further reduction was noticed past this time point.  
 
oxLDL=0: low quartile of oxLDL levels, oxLDL=1: high quartile of oxLDL levels, 0=baseline, 1=one 
month, 2=three months, 3=six months, 4=twelve months. 
Fig. 7. Kaplan Meier survival analysis for the estimation of the risk ratio for restenosis 
according to the levels of oxidized LDL (oxLDL). With red line those with oxLDL levels in 
the highest quartile of the values. With blue line those with oxLDL levels in the lowest 
quartile of the measurements (risk ratio 1.025, logrank test p<0.001).  
The mechanism by which statins modulate oxLDL levels has been controversial in the 
literature. Moreover, the association of oxLDL level modification with improvement of 
carotid atheromatosis and clinical outcome is not unequivocally established by large, 
double-blinded, randomised trials. Under this perspective, the present observational study 
provides reasonable evidence that reducing oxLDL may independently improve carotid 
stenosis. 
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Carotid IMT is a validated measure of carotid atherosclerosis. It is well established that 
carotid atherosclerosis, serves as an independent surrogate marker for CHD (Vasankari et 
al., 2001) and CVD (van Tits et al., 2006). Nevertheless, in the present study it was preferred 
to estimate the degree of carotid stenosis with a more direct approach, because this is more 
readily available in most hospital settings and because there is an obvious relation with 
clinical symptoms and signs. Besides, it represents a reliable method with sufficient 
reproducibility and it is practically the method of choice when evaluated patients candidate 
for endarterectomy or angioplasty. Evaluating carotid stenosis in turn, is an established 
method for estimating coronary risk (Vasankari et al., 2001) and cardiovascular risk (van 
Tits et al., 2006). Other parameters of vessel wall function, such as IMT and plaque 
morphology, even if clearly associated with cardiovascular risk in the literature, require well 
equipped laboratory and are not readily available in our hospital. Future research on the 
field should, ideally, comprise such measurements.  
Oxidized LDL has long been recognized as a risk factor for carotid atherosclerosis in 
asymptomatic men (Liu et al., 2004) and has also been linked with CVD (Robbesyn et al., 
2004). Oxidized LDL levels (Papathanasiou et al., 2008), autoantibodies against epitopes of 
oxLDL (Papathanasiou et al., 2008) and oxLDL:LDL ratio (Vasankari et al., 2001) are 
independently associated with increased risk for coronary atheromatosis and ischemic heart 
disease. Increased levels of oxLDL (Ehara et al., 2001) and MDA-LDL (Holvoet et al., 1999) 
in such cases are related to plaque instability. On the other hand, it has been reported that 
oxLDL is weakly associated with carotid IMT, but not with carotid plaque occurrence 
(Hulthe & Fagerberg, 2002). Oxidized LDL impairs endothelium relaxation (Harrison et al., 
1987) by inhibition of the expression of eNOS and of the transport pathways of nitric oxide 
(NO) from the endothelial cell, reduces the responsiveness of smooth muscle cell to NO 
(Keaney et al., 1996), inhibits the NO-mediated vasodilation (Harrison et al., 1987; Simon et 
al., 1990; Steinberg, 1997), induces the expression of adhesion molecules (Frostegard et al., 
1990), acts directly chemotactic to circulating monocytes (Steinberg, 1997), stimulates 
endothelial cells to produce MCP-1 (Cushing et al., 1990), facilitates monocyte adhesion to 
intima (Mehta et al., 1995), exhibits cytotoxic properties against endothelial cells (Steinberg, 
1997), and induces the expression of inflammatory molecules (Steinberg, 1997). All of the 
above contribute directly to dysfunction of the endothelium (Witztum & Steinberg, 1991) 
and foam cell formation, which is the first step in the development of fatty streaks (Ross, 
1999), the first visible step of atherosclerosis. These effects are mediated by preferential 
binding of oxLDL with type A scavenger receptors (SRA, SRA-II and CD36) on 
subendothelial resident macrophages and smooth muscle cells (Li et al., 1995) and lectin-like 
oxLDL receptor-1 (LOX-1) on endothelial cells (Sawamura et al., 1997) rather than the 
typical LDL receptor, resulting in an unrestricted uptake of cholesterol. 
Statins reduce the incidence of cardiovascular events, an effect attributable to their 
hypocholesterolemic properties (Archbold & Timmis, 1999). However, the extent of clinical 
benefit and accumulating laboratory evidence suggest additional mechanisms of action, the 
so-called pleiotropic effects (Bellosta et al., 2000). The most important among such effects are 
the suppression of smooth muscle cell migration and proliferation (Bellosta et al., 1998), the 
reduction of monocyte adhesion to the vascular endothelium (Weber et al., 1997), the 
improvement of endothelial function (Jarvisalo et al., 1999), the inhibition of cell-mediated 
LDL oxidation (Aviram et al., 1998; Giroux et al., 1993), the immuno-modulation of 
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monocyte maturation and differentiation, and the modification of production of 
inflammatory cytokines (Rothe et al., 1999).  
Atorvastatin suppresses cellular uptake of oxLDL from differentiating monocytes by 
reducing the expression of LOX-1 and scavenger receptors (Fuhrman et al., 2002) and 
accelerates the LDL-receptor-mediated removal of the non oxidized LDL particles 
(Vasankari et al., 2005). Hydroxymetabolites of atorvastatin protect the LDL against 
oxidation (van Tits et al., 2006). The antioxidant potency of atorvastatin metabolites has been 
confirmed by the reduction of IgG antibodies against LDL, a marker well-associated with 
CHD (Aviram et al., 1998). It has even been reported that these active atorvastatin 
metabolites may have greater anti-atherosclerotic effects than other statin molecules (Mason 
et al., 2004).  
In acute coronary syndromes, atorvastatin therapy was linked to modulation of short- and 
long-term immune response towards LDL due to inhibition of lipoprotein-associated 
phospholipase A2 (Lp-LPA2) enzyme (Papathanasiou et al., 2008). The apparent benefit 
from statin therapy after acute coronary events may also be attributed to the stabilization of 
the plaque and removal of oxLDL from the vessel wall (Tsimikas et al., 2004). Increased 
mobilization of oxidized phospholipids from the vessel wall, transient binding with apoB-
100 particles and clearance from the circulation may be the possible underlying mechanism. 
Under this perspective the increase in oxLDL:apoB ratio detected with atorvastatin therapy 
might represent a marker of oxLDL efflux from the vessel wall. Removal of oxLDL 
contributes to improved endothelial function as oxLDL is highly immunogenic and 
vasoconstrictive. In our study there was no significant change in oxLDL:apoB ratio. 
Atorvastatin also inhibits the oxLDL-mediated LOX-1 expression by endothelial cells, the 
uptake of oxLDL in endothelium and the oxLDL-mediated reduction of protein kinase B 
(PKB) phosphorylation (Li et al., 2001). The activation of PKB is critical for the expression of 
eNOS, which promotes vessel relaxation. However, a meta-analysis provided no clear 
evidence that statin therapy have a favourable effect on oxLDL (Balk et al., 2003).  
In STAT trial (Mulder et al., 2007) the antibodies against oxLDL were equally decreased with 
both aggressive and conventional lipid-lowering therapy. This indicates that the statin-related 
reduction of oxLDL is not a dose-dependent phenomenon, a finding which is in agreement 
with our results. It might therefore represent a pleiotropic effect, independent -at least 
partially- from the hypo-cholesterolemic action. A study by Orem et al. (2002) detected a 
significant decrease of autoantibodies against oxLDL with low doses of atorvastatin (10 mg), 
similar to doses used in our study. In statin exposed patients, intensification of the regimen 
offers no additional benefit and only those with LDL >125 mg/dl benefited from a more 
aggressive statin therapy (Mulder et al., 2007). Statins have a dose-related response with 
regard to clinical outcome, but this dose-related response has not been confirmed with regard 
to oxidative stress (Ky et al., 2008). This might alternatively be explained by the hypothesis 
that statins achieve their uttermost benefit on oxLDL within a certain time point (Mulder et al., 
2007), after which further continuation of treatment serves only the purpose of maintenance. 
Atorvastatin has been shown to reduce small dense LDL subfractions, remnant-like particles 
cholesterol and oxLDL, and improve endothelial function, after just few weeks of therapy 
(Miyagishima et al., 2007; Sakabe et al., 2003). Such time-related effect has not been fully 
elucidated, but may possibly account for our finding that in the first six months there was an 
accelerated decline of oxLDL levels followed by a milder reduction rate thereafter.  
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Additional pleiotropic effects of statins have been reported in the literature and might 
account for the observed beneficial effects in the current study. Lysophosphatidylcholine is 
elevated during LDL oxidation and is responsible for some of the biological effects of 
oxLDL. Atorvastatin alters the ability of oxLDL to impair the endothelium relaxation, by 
modulating the hydrolysis of phosphatidylcholine to lysophosphatidylcholine when LDL is 
being oxidized (Zhu et al., 2000). Statins remove predominately "aged LDL" from plasma, 
which is more prone to oxidation (Orem et al., 2002), through stimulation of hepatic LDL 
receptor activity and inhibition of very-low density lipoprotein (VLDL) and LDL production 
by the liver cells (Orem et al., 2002). Statins also reduce oxygen species generation (Ky et al., 
2008). Atorvastatin promotes adipocyte uptake of oxLDL in rabbits by increasing the 
expression of CD36 and peroxisome proliferators-activated receptor γ (PPARγ) in 
adipocytes (Zhao & Zhang, 2004). The increased expression of such receptors by adipocytes 
results to internalization of oxLDL and clearance from plasma, converting adipocytes to an 
oxLDL-buffering pool (Zhao & Zhang, 2004). Reduction of oxLDL in patients with CHD 
with atorvastatin 10 mg parallel with an increase of adiponectin, which has anti-atherogenic, 
anti-inflammatory and anti-diabetic properties through reduction of insulin resistance 
(Miyagishima et al., 2007). The CARDS study reported a significant degree of preventive 
activity of atorvastatin against myocardial infarction in eucholesterolemic diabetic patients, 
conceivably attributed to such improvement of insulin sensitivity (Miyagishima et al., 2007). 
Statins also diminish the expression of CD40 and CD40 ligand in vascular cells, smooth 
muscle cells and macrophages, which are promoted by oxLDL and are considered 
proatherogenic (Schonbeck et al., 2002). Other anti-inflammatory pathways include 
reduction of C-reactive protein (Hogue et al., 2008), chemokines, major histocompatibility 
complex II molecules, matrix-degrading enzymes, and procoagulant tissue factor 
(Schonbeck et al., 2002). Atorvastatin reverses the oxLDL-mediated inhibition of vascular 
endothelial growth factor-induced endothelial progenitor cell differentiation via the 
phosphatidylinositol 3 kinase/Akt pathway (Imanishi et al., 2003), which restores the 
oxLDL-related inhibition of mature endothelial cells migration (Imanishi et al., 2003). This 
could improve neovascularization and collateral vessel formation in response to tissue 
ischemia. Atorvastatin also suppresses platelet activity (Puccetti et al., 2005) by reducing the 
expression of CD36 and LOX-1, which are present in platelets (Puccetti et al., 2005; 
Sawamura et al., 1997), thus inhibiting the oxLDL-mediated platelet hyperactivity (Puccetti 
et al., 2005). Statins reduce the oxLDL-derived expression of adhesion molecules (E- and P-
selectins, vascular cell adhesion molecule 1 [VCAM-1] and intercellular adhesion molecule 1 
[ICAM-1]) in human coronary artery endothelial cells, through up-regulation of eNOS 
expression, which regulates the expression of adhesion molecules in endothelial cells (Li et 
al., 2002). Statins also diminish the oxLDL-mediated activation of nuclear factor-κΒ (NF-κB) 
(D. Li et al., 2002), which regulates the transcription of adhesion molecule genes (Robbesyn 
et al., 2004). In diabetic patients with dyslipidemia atorvastatin reduced CVD and markers 
of inflammation, adhesion and oxidation, such as C-reactive protein (CRP), soluble ICAM-1, 
soluble VCAM-1, E-selectin, matrix metalloproteinase 9, secretory phospholipase A2 
(sPLA2), and oxLDL, the latter by 38,4% (Hogue et al., 2008). Moreover, the change of 
oxLDL levels correlated with the change of sICAM-1 and E-selectin levels, suggesting that 
statins could possibly counteract the oxLDL-associated increase of NF-κΒ, and therefore, the 
production of such cell adhesion molecules (Hogue et al., 2008). Statins also enhance 
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scavenger receptor expression in macrophages, and increase plaque stability via reduction 
of metalloproteinases (Hogue et al., 2008).  
The reduction of oxLDL and of carotid stenosis in our study was relevant for both smokers 
and non-smokers. However, subsequent subgroup analysis showed that the beneficial effect 
of statin use concerns mostly the subgroup of mild smokers, while no such effect was 
noticed for moderate and heavy smokers. How smoking may diminish the beneficial effect 
of statins on oxLDL and carotid stenosis is not yet clarified in the literature. A reasonable 
assumption might be that, since smoking increases the oxidative stress, it contributes to 
enhanced LDL oxidation (Van Himbergen et al., 2004). Moreover, studies in animal models, 
have demonstrated that smoking alters the immunologic response to oxLDL by reducing the 
production of antibodies against these molecules, i.e. causing a kind of immune suppression 
regarding the response to oxLDL. Thus, it has been shown to increase carotid IMT (Tani et 
al., 2004).  
The Mercodia oxLDL detects the MDA-modified apoB (Holvoet et al., 1996). It has been 
proposed that oxLDL looses its predictive value for CVD when adjustment for apoB level is 
performed (Ky et al., 2008). In several studies though, a significant reduction of Mercodia 
oxLDL with atorvastatin 10 mg was still detected even after adjustment for apoB, (Holvoet 
et al., 2003; Ky et al., 2008; van Tits et al., 2006), while in other studies no adjustment for LDL 
or apoB levels was made (Ky et al., 2008; Sasaki et al., 2002). In our study the oxLDL:apoB 
ratio remained unchanged, but in the multivariate analysis the reduction of oxLDL was still 
significant after adjustment for apoB and LDL levels. 
In patients with familial hypercholesterolemia a lack of association between oxLDL and IMT 
was reported at baseline, however two years therapy with atorvastatin 80 mg was 
associated with regression of carotid IMT (van Tits et al., 2004). The LDL subfraction profile 
and autoantibodies against oxLDL remained unchanged. Nevertheless, the rate of oxidation 
and the amount of dienes formed decreased and this was linked to lessening of 
atherosclerosis. In our study the reduction of carotid stenosis was associated with decreased 
oxLDL levels. Besides, the unchanged oxLDL autoantibodies levels do not preclude the 
reduction of oxLDL, as was indicated in another study involving dialysis patients, where 
atorvastatin therapy reduced plasma oxLDL, whereas oxLDL autoantibodies did not 
changed significantly (van den Akker et al., 2003).  
Disadvantages of the study were the relatively small size, the lack of a control group 
comprising of patients with carotid stenosis not on statin therapy, which would be 
unethical, the fact that researchers were not blinded to the patients’ status, the lack of 
randomization of the dose-schedules and the use of only one method to detect oxLDL. 
5. Conclusion 
This prospective, cross-sectional study with such a long observation period provided 
enough evidence to postulate a favourable effect of low-dose atorvastatin therapy on 
oxLDL, which was additionally associated with improvement of stenosis in patients with 
carotid atheromatosis. We thus, assume that oxLDL may represent a far more sensitive risk 
factor for carotid stenosis, than LDL itself or apoB. Further studying is required to confirm 
such findings and to establish a clear clinical and pathophsiologic link between oxLDL and 
carotid stenosis. 
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